TGF-β: the master regulator of fibrosis

Xiao-Ming Meng; David J. Nikolic-Paterson; Hui Yao Lan

doi:10.1038/nrneph.2016.48

journal article Apr 25, 2016

TGF-β: the master regulator of fibrosis

Xiao-Ming Meng David J. Nikolic-Paterson Hui Yao Lan

Nature Reviews Nephrology Vol. 12 No. 6 pp. 325-338 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrneph.2016.48

Topics

No keywords indexed for this article. Browse by subject →

References

251

[1]

Eddy, A. A. & Neilson, E. G. Chronic kidney disease progression. J. Am. Soc. Nephrol. 17, 2964–2966 (2006). 10.1681/asn.2006070704

[2]

Bottinger, E. P. & Bitzer, M. TGF-β signaling in renal disease. J. Am. Soc. Nephrol. 13, 2600–2610 (2002). 10.1097/01.asn.0000033611.79556.ae

[3]

Eddy, A. A. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int. Suppl. (2011) 4, 2–8 (2014). 10.1038/kisup.2014.2

[4]

Sharma, K. et al. Increased renal production of transforming growth factor-β1 in patients with type II diabetes. Diabetes 46, 854–859 (1997). 10.2337/diab.46.5.854

[5]

Yamamoto, T., Nakamura, T., Noble, N. A., Ruoslahti, E. & Border, W. A. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc. Natl Acad. Sci. USA 90, 1814–1818 (1993). 10.1073/pnas.90.5.1814

[6]

Yoshioka, K. et al. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab. Invest. 68, 154–163 (1993).

[7]

Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B. & Ruoslahti, E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346, 371–374 (1990). 10.1038/346371a0

[8]

Isaka, Y. et al. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. 92, 2597–2601 (1993). 10.1172/jci116874

[9]

Moon, J. A., Kim, H. T., Cho, I. S., Sheen, Y. Y. & Kim, D. K. IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 70, 1234–1243 (2006). 10.1038/sj.ki.5001775

[10]

Russo, L. M., del Re, E., Brown, D. & Lin, H. Y. Evidence for a role of transforming growth factor (TGF)-β1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-β type II receptor. Diabetes 56, 380–388 (2007). 10.2337/db06-1018

[11]

Sato, M., Muragaki, Y., Saika, S., Roberts, A. B. & Ooshima, A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112, 1486–1494 (2003). 10.1172/jci200319270

[12]

Meng, X. M., Chung, A. C. & Lan, H. Y. Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin. Sci. (Lond.) 124, 243–254 (2013). 10.1042/cs20120252

[13]

Zhang, Y. E. Non-Smad pathways in TGF-β signaling. Cell Res. 19, 128–139 (2009). 10.1038/cr.2008.328

[14]

Yu, L., Border, W. A., Huang, Y. & Noble, N. A. TGF-β isoforms in renal fibrogenesis. Kidney Int. 64, 844–856 (2003). 10.1046/j.1523-1755.2003.00162.x

[15]

Xu, P., Liu, J. & Derynck, R. Post-translational regulation of TGF-β receptor and Smad signaling. FEBS Lett. 586, 1871–1884 (2012). 10.1016/j.febslet.2012.05.010

[16]

Sanderson, N. et al. Hepatic expression of mature transforming growth factor β 1 in transgenic mice results in multiple tissue lesions. Proc. Natl Acad. Sci. USA 92, 2572–2576 (1995). 10.1073/pnas.92.7.2572

[17]

Robertson, I. B. et al. Latent TGF-β-binding proteins. Matrix Biol. 47, 44–53 (2015). 10.1016/j.matbio.2015.05.005

[18]

Annes, J. P., Munger, J. S. & Rifkin, D. B. Making sense of latent TGFβ activation. J. Cell Sci. 116, 217–224 (2003). 10.1242/jcs.00229

[19]

Probst-Kepper, M., Balling, R. & Buer, J. FOXP3: required but not sufficient. The role of GARP (LRRC32) as a safeguard of the regulatory phenotype. Curr. Mol. Med. 10, 533–539 (2010).

[20]

Mice overexpressing latent TGF-β1 are protected against renal fibrosis in obstructive kidney disease

Xiao R. Huang, Arthur C. K. Chung, Xiao J. Wang et al.

American Journal of Physiology-Renal Physiology 2008 10.1152/ajprenal.00021.2008

[21]

Huang, X. R., Chung, A. C., Zhou, L., Wang, X. J. & Lan, H. Y. Latent TGF-β1 protects against crescentic glomerulonephritis. J. Am. Soc. Nephrol. 19, 233–242 (2008). 10.1681/asn.2007040484

[22]

Border, W. A., Okuda, S., Languino, L. R. & Ruoslahti, E. Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int. 37, 689–695 (1990). 10.1038/ki.1990.35

[23]

Haberstroh, U. et al. TGF-β stimulates rat mesangial cell proliferation in culture: role of PDGF beta-receptor expression. Am. J. Physiol. 264, F199–F205 (1993).

[24]

Wilson, H. M. et al. Effect of transforming growth factor-beta 1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells. Exp. Nephrol. 1, 343–350 (1993).

[25]

Lopez-Hernandez, F. J. & Lopez-Novoa, J. M. Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 347, 141–154 (2012). 10.1007/s00441-011-1275-6

[26]

Gruden, G., Perin, P. C. & Camussi, G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr. Diabetes Rev. 1, 27–40 (2005). 10.2174/1573399052952622

[27]

Neelisetty, S. et al. Renal fibrosis is not reduced by blocking transforming growth factor-β signaling in matrix-producing interstitial cells. Kidney Int. 88, 503–514 (2015). 10.1038/ki.2015.51

[28]

Meng, X. M. et al. Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro. J. Pathol. 227, 175–188 (2012). 10.1002/path.3976

[29]

Gewin, L. et al. TGF-β receptor deletion in the renal collecting system exacerbates fibrosis. J. Am. Soc. Nephrol. 21, 1334–1343 (2010). 10.1681/asn.2010020147

[30]

Lebrin, F., Deckers, M., Bertolino, P. & Ten Dijke, P. TGF-β receptor function in the endothelium. Cardiovasc. Res. 65, 599–608 (2005). 10.1016/j.cardiores.2004.10.036

[31]

Das, R. et al. Upregulation of mitochondrial Nox4 mediates TGF-β-induced apoptosis in cultured mouse podocytes. Am. J. Physiol. Renal Physiol. 306, F155–F167 (2014). 10.1152/ajprenal.00438.2013

[32]

Mack, M. & Yanagita, M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int. 87, 297–307 (2015). 10.1038/ki.2014.287

[33]

Chen, S. J. et al. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3. J. Invest. Dermatol. 112, 49–57 (1999). 10.1046/j.1523-1747.1999.00477.x

[34]

Yuan, W. & Varga, J. Transforming growth factor-β repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J. Biol. Chem. 276, 38502–38510 (2001). 10.1074/jbc.m107081200

[35]

Dennler, S. et al. Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17, 3091–3100 (1998). 10.1093/emboj/17.11.3091

[36]

Piek, E. et al. Functional characterization of transforming growth factor β signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem. 276, 19945–19953 (2001). 10.1074/jbc.m102382200

[37]

Goumans, M. J. & Mummery, C. Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int. J. Dev. Biol. 44, 253–265 (2000).

[38]

Inazaki, K. et al. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int. 66, 597–604 (2004). 10.1111/j.1523-1755.2004.00779.x

[39]

Kim, J. H., Kim, B. K., Moon, K. C., Hong, H. K. & Lee, H. S. Activation of the TGF-β/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int. 64, 1715–1721 (2003). 10.1046/j.1523-1755.2003.00288.x

[40]

Fujimoto, M. et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 305, 1002–1007 (2003). 10.1016/s0006-291x(03)00885-4

[41]

Zhou, L. et al. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am. J. Physiol. Renal Physiol. 298, F1006–F1017 (2010). 10.1152/ajprenal.00675.2009

[42]

Meng, X. M. et al. Smad2 protects against TGF-β/Smad3-mediated renal fibrosis. J. Am. Soc. Nephrol. 21, 1477–1487 (2010). 10.1681/asn.2009121244

[43]

Tsuchida, K., Zhu, Y., Siva, S., Dunn, S. R. & Sharma, K. Role of Smad4 on TGF-β-induced extracellular matrix stimulation in mesangial cells. Kidney Int. 63, 2000–2009 (2003). 10.1046/j.1523-1755.2003.00009.x

[44]

Meng, X. M. et al. Disruption of Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int. 81, 266–279 (2012). 10.1038/ki.2011.327

[45]

Yan, X. & Chen, Y. G. Smad7: not only a regulator, but also a cross-talk mediator of TGF-β signalling. Biochem. J. 434, 1–10 (2011). 10.1042/bj20101827

[46]

Shi, Y. & Massague, J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685–700 (2003). 10.1016/s0092-8674(03)00432-x

[47]

Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice

Hirotaka Fukasawa, Tatsuo Yamamoto, Akashi Togawa et al.

Proceedings of the National Academy of Sciences 2004 10.1073/pnas.0400035101

[48]

Chung, A. C. et al. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol. Dial. Transplant. 24, 1443–1454 (2009). 10.1093/ndt/gfn699

[49]

Chen, H. Y. et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60, 590–601 (2011). 10.2337/db10-0403

[50]

Liu, G. X. et al. Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/Smad3-NF.κB-dependent mechanisms in mice. PLoS ONE 8, e53573 (2013). 10.1371/journal.pone.0053573

Showing 50 of 251 references

Cited By

3,104

Estrogen upregulates NR4A1 to counter TGF beta induced pulmonary fibrosis therapeutic insights for IPF

Bao Liu, Haoran Chi · 2026

iScience

Anti-inflammatory and antioxidant effects of salidroside in diabetic nephropathy: a systematic review and meta-analysis of preclinical studies

Di Sun, Jin Peng · 2026

Frontiers in Pharmacology

Clinical efficacy analysis of high-intensity focused ultrasound ablation in treating fibroadenomas of different breast gland types: a retrospective study

Dongmin Yu, Kang He · 2026

PeerJ

Klotho-derived peptide preserves erectile function by limiting fibrosis, oxidative stress, and apoptosis of penile smooth muscle cells in cavernous nerve injured-rats through suppression of the TGF-β1/TGF-β type II receptor signaling

Yuhang Xi, Guangye Han · 2026

European Journal of Pharmacology

Anthraquinones from Rheum officinale Ameliorate Renal Fibrosis in Acute Kidney Injury and Chronic Kidney Disease

Hao-Yu Feng, Yi-Qi Wang · 2025

Drug Design, Development and Therap...

Lipid nanoparticles with prazole adjuvant to enhance the efficacy of mRNA cancer vaccines

Hayoon Jeong, Hongjae Kim · 2025

Journal of Controlled Release

Cathepsin K Aggravates Pulmonary Fibrosis Through Promoting Fibroblast Glutamine Metabolism and Collagen Synthesis

Mengting Chen, Xiaoxiao Meng · 2025

Advanced Science

Matrix-producing neutrophils populate and shield the skin

Tommaso Vicanolo, Alaz Özcan · 2025

Nature

Molecular signaling pathways in doxorubicin-induced nephrotoxicity and potential therapeutic agents

Changxu Lu, Jinwen Wei · 2025

International Immunopharmacology

PRDM16 acts as a therapeutic downstream target of TGF-β signaling in chronic kidney disease

Qian Yuan, Ben Tang · 2025

JCI Insight

Trim21 mediates metabolic reprogramming in renal tubular cells via PFKP ubiquitination to alleviate renal fibrosis

Yang Wen, Maoqing Tian · 2024

Journal of Cellular Physiology

Lysine acetyltransferase 14 mediates TGF-β-induced fibrosis in ovarian endometrioma via co-operation with serum response factor

Yi Gong, Mian Liu · 2024

Journal of Translational Medicine

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer

Mindy K. Graham, Rulin Wang · 2024

Nature Communications

High glucose elevates intracellular calcium level and induces ferroptosis in glomerular endothelial cells through the miR-223-3p/ITPR3 pathway

Dekai Wang, Lihua Zhang · 2024

Molecular and Cellular Endocrinolog...

Butyrate modulates gut microbiota and anti-inflammatory response in attenuating cisplatin-induced kidney injury

Wen-Jung Chen, Yng-Tay Chen · 2024

Biomedicine & Pharmacotherapy

Dextromethorphan inhibits collagen and collagen-like cargo secretion to ameliorate lung fibrosis

Muzamil M. Khan, George Galea · 2024

Science Translational Medicine

The effect of extracorporeal shock wave on joint capsule fibrosis in rats with knee extension contracture: a preliminary study

Chao Hu, Quan Bing Zhang · 2023

Connective Tissue Research

Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies

Lixiang Feng, Xingyu Chen · 2023

Frontiers in Pharmacology

Effects of Resveratrol on Pulmonary Fibrosis via TGF-β/Smad/ERK Signaling Pathway

Lei Liu, Bin Liu · 2023

The American Journal of Chinese Med...

Anlotinib Alleviates Renal Fibrosis via Inhibition of the ERK and AKT Signaling Pathways

Donglin Sun, Jing Guo · 2023

Oxidative Medicine and Cellular Lon...

Metrics

3,104

Citations

251

References

Details

Published: Apr 25, 2016
Vol/Issue: 12(6)
Pages: 325-338
License: View

Authors

X

Xiao-Ming Meng

D

David J. Nikolic-Paterson

H

Hui Yao Lan

Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China

Cite This Article

Xiao-Ming Meng, David J. Nikolic-Paterson, Hui Yao Lan (2016). TGF-β: the master regulator of fibrosis. Nature Reviews Nephrology, 12(6), 325-338. https://doi.org/10.1038/nrneph.2016.48

TGF-β: the master regulator of fibrosis

You May Also Like